Description
Provider of a novel drug discovery platform designed to generate a broad pipeline of first-in-class drugs. The company's novel drug discovery platform analyzes thousands of compounds and have a capacity to reproduce the process of massive molecule testing in vivo using Drosophila individuals enabling the development of additional drugs to treat human diseases.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 01-Feb-2016 | Completed | Out of Business | |||
1. Early Stage VC | 26-Jun-2008 | Completed | Startup |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-2931374-A1 | Phenanthrene derivatives for use as medicaments | Inactive | 13-Dec-2012 | 0000000000 | |
EP-2742974-A1 | Phenanthrene derivatives for use as medicaments | Inactive | 13-Dec-2012 | 0000000000 | |
US-20160194274-A1 | Phenanthrene derivatives for use as medicaments | Inactive | 13-Dec-2012 | C07C217/74 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Rebeca Lucas | Co-Founder & Chief Executive Officer | ||
Manuel Perez-Alonso Ph.D | Co-Founder & Scientific Director |